Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk.
J Intern MedAug 30, 2026 (epub)
Maria Forslund, Johanna Melin, Anju E Joham et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review discusses polyendocrine metabolic ovarian syndrome (PMOS), affecting 10%-13% of reproductive-age women, emphasizing its recognition as a lifelong endocrine and metabolic disorder. Key findings include an almost 3-fold increased risk of Type 2 diabetes (OR 2.9) and major adverse cardiovascular events (MACE) (HR 1.2-2.5), with cardiovascular risk diverging from age 35.
Key findings
- Insulin resistance affects 75% of lean and 95% of overweight women with PMOS.
- PMOS is associated with an almost 3-fold increased risk of Type 2 diabetes (OR 2.9).
- The risk of major adverse cardiovascular events (MACE) is increased (HR 1.2-2.5).
- Cardiovascular risk diverges from approximately 35 years of age.
Why it matters
Understanding PMOS as a multisystem condition with significant metabolic and cardiovascular implications is crucial for early diagnosis and management. This recognition can lead to improved patient outcomes through targeted interventions and risk stratification.